Radiation Therapy for T2N0 Glottic Cancer.
- Author:
Jae Chul KIM
1
Author Information
1. Department of Radiation Oncology, Kyungpook National University School of Medicine, Daegu, Korea. jckim@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Glottic cancer;
Radiation therapy
- MeSH:
Carcinoma, Squamous Cell;
Disease-Free Survival;
Drug Therapy;
Follow-Up Studies;
Humans;
Male;
Particle Accelerators;
Retrospective Studies;
Survival Rate
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2006;24(4):217-222
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study evaluated the results of definitive radiation therapy and the prognostic factors that affect survival rates for T2N0 glottic cancer patients. MATERIALS AND METHODS: Thirty patients with T2N0 glottic cancer who were treated with definitive radiation therapy at our institution between September 1986 and June 2004 were retrospectively reviewed. All patients were pathologically confirmed as having squamous cell carcinoma and were staged as AJCC T2N0. The age of the patients ranged from 39 to 79 (median 62) years and all were male. A total dose of 66~70 Gy (median 66 Gy) was delivered with a 6-MV linear accelerator in 6.5~7 weeks. The median follow-up period was 63 months. RESULTS: The actuarial disease-free survival rate for the entire group of the patients was 79% at 5 years. The five-year disease-free survival rates for patients without and with subglottic extension were 90% and 56%, respectively (p=0.03). However, anterior commissure involvement, supraglottic extension, and impaired cord mobility were not statistically significant prognostic factors. The five-year disease-free survival rates for patients with and without concurrent chemotherapy were 86% and 69%, respectively (p=0.47). CONCLUSION: Subglottic extension can be considered a poor prognostic factor for T2N0 glottic cancer.
